Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Amortizatization of Intangibles: 2019-2025

Historic Amortizatization of Intangibles for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to $1.7 million.

  • C4 Therapeutics' Amortizatization of Intangibles rose 4.58% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 4.45%. This contributed to the annual value of $6.4 million for FY2024, which is 4.25% up from last year.
  • C4 Therapeutics' Amortizatization of Intangibles amounted to $1.7 million in Q3 2025, which was up 1.20% from $1.7 million recorded in Q2 2025.
  • Over the past 5 years, C4 Therapeutics' Amortizatization of Intangibles peaked at $1.7 million during Q2 2022, and registered a low of -$1.7 million during Q3 2021.
  • Moreover, its 3-year median value for Amortizatization of Intangibles was $1.6 million (2024), whereas its average is $1.6 million.
  • As far as peak fluctuations go, C4 Therapeutics' Amortizatization of Intangibles crashed by 927.09% in 2021, and later soared by 421.71% in 2022.
  • C4 Therapeutics' Amortizatization of Intangibles (Quarterly) stood at -$847,000 in 2021, then soared by 277.33% to $1.5 million in 2022, then rose by 4.06% to $1.6 million in 2023, then climbed by 4.35% to $1.6 million in 2024, then climbed by 4.58% to $1.7 million in 2025.
  • Its last three reported values are $1.7 million in Q3 2025, $1.7 million for Q2 2025, and $1.6 million during Q1 2025.